In adult aged 18 years and older with Type-II diabetic mellitus to improve glycemic control: As mono-therapy when diet and exercise alone do not provide adequate glycemic control in patients for whom use of metformin is considered inappropriate due to intolerance. As add-on combination therapy in combination therapy in combination with other glucose- lowering medicinal products including insulin, when these, together with diet and exercise, do notprovide adequate glycemic control.
In the proximal tubules, Sodium-glucose cotransporter 2 (SGLT2) plays a major role in reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of sodium-glucose co-transporter 2 (SGLT2) that improves glycaemic control in patients with T2DM by reducing renal glucose reabsorption leading to urinary excretion of excess glucose.
One tablet, once daily, with or without food.
Patients who have a history of hypersensitivity to the Dapagliflozin. Patients with severe renal impairment, (eGFR less than 30 mL/min/1.73 m2) end-stage renal disease (ESRD), or patients on dialysis.
Caution should be exercised, while administering Zucapride in patients with hypotension, ketoacidosis, acute kidney injury, urosepsis and polynephritis, hypoglycaemia, necrotizing fasciitis of the perineum (Fournier’s Gangrene) and genital myotic infections.
Pregnancy: Advise females of the potential risk to a fetus especially during the second and third trimesters. Lactation: Not recommended when breastfeeding.Safety and effectiveness in paediatric patients under 18 years of age have not been established.
Positive Urine Glucose Test: SGLT2 inhibitors increase urine glucose, which might lead to false positive results. Interference with 1,5-anhydroglucitol (1,5-AG) Assay: Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors.
Male and female genital mycotic infections, hypotension, ketoacidosis, nasopharyngitis, UTI, back pain, increased micturition, nausea, constipation, dyslipidaemia and influenza.